Abstract
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
Highlights
Differentiated thyroid cancer (DTC) accounts for more than 90% of all thyroid cancers
An increasing incidence of DTC, mainly due to cancers of papillary histology, has been reported in many countries in- and outside of Europe [1, 2]. This increase is largely attributable to a better detection of small papillary thyroid carcinomas (PTC), as a result of screening bias [3]
Low-risk patients with post-operatively detectable serum Tg, in particular when it is above the institutional cut-off of, for example, 2 ng/mL on l-T4 or >5–10 ng/mL after thyroid-stimulating hormone (TSH) stimulation or with abnormal ultrasound findings have a higher risk of recurrence, and radioactive iodine (RAI) therapy may be considered, there is no evidence that it can improve disease-free survival
Summary
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
